Rodger EJ, Gimenez G, Ajithkumar P, Stockwell PA, Almomani S, Bowden SA, Leichter AL, Ahn A, Pattison S, McCall JL, Schmeier S, Frizelle FA, Eccles MR, Purcell RV, Chatterjee A. An epigenetic signature of advanced colorectal cancer metastasis. iScience. 2023 May 28.
Ahmed F, Tseng HY, Ahn A, Gunatilake D, Alavi S, Eccles M, Rizos H, Gallagher SJ, Tiffen JC, Hersey P, Emran AA. Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma. J Invest Dermatol. 2022 May
Chatterjee A, Rodger EJ, Ahn A, Stockwell PA, Parry M, Motwani J, Gallagher SJ, Shklovskaya E, Tiffen J, Eccles MR, Hersey P: Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma. iScience 2018, 4:312-325.
Chatterjee A, Ahn A, Rodger EJ, Stockwell PA, Eccles MR: A Guide for Designing and Analyzing RNA-Seq Data. Methods Mol Biol 2018, 1783:35-80.
Ahn A, Chatterjee A, Eccles MR: The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma. Mol Cancer Ther 2017, 16:1002-1009.
Chatterjee A, Stockwell PA, Ahn A, Rodger EJ, Leichter AL, Eccles MR: Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis. Oncotarget 2017, 8:6085-6101.
Chatterjee A, Macaulay EC, Ahn A, Ludgate JL, Stockwell PA, Weeks RJ, Parry MF, Foster TJ, Knarston IM, Eccles MR, Morison IM: Comparative assessment of DNA methylation patterns between reduced representation bisulfite sequencing and Sequenom EpiTyper methylation analysis. Epigenomics 2017, 9:823-832.
Jones AM, Ferguson P, Gardner J, Rooker S, Sutton T, Ahn A, Chatterjee A, Bickley VM, Sarwar M, Emanuel P, et al: NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand. Oncotarget 2016, 7:41017-41030.
Royds JA, Pilbrow AP, Ahn A, Morrin HR, Frampton C, Russell IA, Moravec CS, Sweet WE, Tang WH, Currie MJ, et al: The rs11515 Polymorphism Is More Frequent and Associated With Aggressive Breast Tumors with Increased ANRIL and Decreased p16 (INK4a) Expression. Front Oncol 2015, 5:306.
Ahn A, Eccles MR: Targeted therapy; from advanced melanoma to the adjuvant setting. Front Oncol 2013, 3:205.
Eccles MR, He S, Ahn A, Slobbe LJ, Jeffs AR, Yoon HS, Baguley BC: MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a “Genetic Switch” Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma. Front Oncol 2013, 3:229.
Royds JA, Al Nadaf S, Wiles AK, Chen YJ, Ahn A, Shaw A, Bowie S, Lam F, Baguley BC, Braithwaite AW, et al: The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS One 2011, 6:e26737.